Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma

Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp

Detalles Bibliográficos
Autores principales: Noorduyn, Stephen G., Johnston, Karissa, Osenenko, Kathy, Sriskandarajah, Niroshan, Gendron, Alain, Mbuagbaw, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645999/
https://www.ncbi.nlm.nih.gov/pubmed/34881326
http://dx.doi.org/10.1183/23120541.00465-2021
Descripción
Sumario:Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp

Ejemplares similares